248 related articles for article (PubMed ID: 33444661)
21. Cell expression patterns of CD147 in N-diethylnitrosamine/phenobarbital-induced mouse hepatocellular carcinoma.
Lu M; Wu J; He F; Wang XL; Li C; Chen ZN; Bian H
J Mol Histol; 2015 Feb; 46(1):79-91. PubMed ID: 25447507
[TBL] [Abstract][Full Text] [Related]
22. Identification of potential targets with high centrality indicated by diethylnitrosamine + thioacetamide-induced hepatocellular carcinoma model.
Hora S; Asad M; Jain SK; Katare DP
J Cancer Res Ther; 2021; 17(4):1081-1092. PubMed ID: 34528568
[TBL] [Abstract][Full Text] [Related]
23. Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis.
Liu CH; Chan KM; Chiang T; Liu JY; Chern GG; Hsu FF; Wu YH; Liu YC; Chen Y
Mol Pharm; 2016 Jul; 13(7):2253-62. PubMed ID: 27224003
[TBL] [Abstract][Full Text] [Related]
24. Stem cell and hepatocyte proliferation in hepatitis C cirrhosis and hepatocellular carcinoma: transplant implications.
Behnke MK; Reimers M; Fisher RA
Ann Hepatol; 2013 Jan-2014 Feb; 13(1):45-53. PubMed ID: 24378265
[TBL] [Abstract][Full Text] [Related]
25. Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine.
Ding YF; Wu ZH; Wei YJ; Shu L; Peng YR
J Cancer Res Clin Oncol; 2017 May; 143(5):821-834. PubMed ID: 28238064
[TBL] [Abstract][Full Text] [Related]
26. The DEN and CCl4 -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma.
Uehara T; Pogribny IP; Rusyn I
Curr Protoc Pharmacol; 2014 Sep; 66():14.30.1-14.30.10. PubMed ID: 25181010
[TBL] [Abstract][Full Text] [Related]
27. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
[TBL] [Abstract][Full Text] [Related]
28. Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background.
Chung SI; Moon H; Kim DY; Cho KJ; Ju HL; Kim DY; Ahn SH; Han KH; Ro SW
BMC Gastroenterol; 2016 Jan; 16():13. PubMed ID: 26821924
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-like proteins tip regenerative balance in the liver to favour cancer formation.
Fifield BA; Talia J; Stoyanovich C; Elliott MJ; Bakht MK; Basilious A; Samsoondar JP; Curtis M; Stringer KF; Porter LA
Carcinogenesis; 2020 Jul; 41(6):850-862. PubMed ID: 31574533
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
31. Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.
Matsuda M; Seki E
Semin Liver Dis; 2020 Aug; 40(3):307-320. PubMed ID: 32242330
[TBL] [Abstract][Full Text] [Related]
32. Branched-chain amino acids ameliorate fibrosis and suppress tumor growth in a rat model of hepatocellular carcinoma with liver cirrhosis.
Cha JH; Bae SH; Kim HL; Park NR; Choi ES; Jung ES; Choi JY; Yoon SK
PLoS One; 2013; 8(11):e77899. PubMed ID: 24223741
[TBL] [Abstract][Full Text] [Related]
33. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.
Reiberger T; Chen Y; Ramjiawan RR; Hato T; Fan C; Samuel R; Roberge S; Huang P; Lauwers GY; Zhu AX; Bardeesy N; Jain RK; Duda DG
Nat Protoc; 2015 Aug; 10(8):1264-74. PubMed ID: 26203823
[TBL] [Abstract][Full Text] [Related]
34. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
[TBL] [Abstract][Full Text] [Related]
35. Analysis of potential key genes in very early hepatocellular carcinoma.
Wu M; Liu Z; Li X; Zhang A; Lin D; Li N
World J Surg Oncol; 2019 May; 17(1):77. PubMed ID: 31043166
[TBL] [Abstract][Full Text] [Related]
36. Vascular density and VEGF expression in hepatic lesions.
Brodsky SV; Mendelev N; Melamed M; Ramaswamy G
J Gastrointestin Liver Dis; 2007 Dec; 16(4):373-7. PubMed ID: 18193117
[TBL] [Abstract][Full Text] [Related]
37. Contributions of Fibroblasts, Extracellular Matrix, Stiffness, and Mechanosensing to Hepatocarcinogenesis.
Filliol A; Schwabe RF
Semin Liver Dis; 2019 Jul; 39(3):315-333. PubMed ID: 31226725
[TBL] [Abstract][Full Text] [Related]
38. Abberent expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma.
Chen S; Zheng P; Wang W; Yi M; Chen P; Cai J; Li J; Peng Q; Ban Y; Zhou Y; Zeng Z; Li X; Xiong W; Li G; Xiang B
J Cell Physiol; 2018 Jun; 233(6):5002-5013. PubMed ID: 29227538
[TBL] [Abstract][Full Text] [Related]
39. Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer.
Lau JKC; Zhang X; Yu J
Adv Exp Med Biol; 2018; 1061():139-147. PubMed ID: 29956212
[TBL] [Abstract][Full Text] [Related]
40. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma.
Shankaraiah RC; Callegari E; Guerriero P; Rimessi A; Pinton P; Gramantieri L; Silini EM; Sabbioni S; Negrini M
Oncogene; 2019 Nov; 38(45):7035-7045. PubMed ID: 31409896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
